Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDP1503 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- Evelo Biosciences
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
EDP1503 + pembrolizumab is a combination therapy consisting of EDP1503, a monoclonal microbial product, and pembrolizumab (Keytruda), an anti-PD-1 therapy. EDP1503 is designed to activate multiple systemic immune pathways that are complementary to and potentially synergistic with checkpoint inhibitors. In preclinical studies, orally delivered EDP1503 showed activation of multiple clinically validated systemic immune pathways, including increased CXCL9 and CXCL10 production in the tumor microenvironment, augmentation of NK and T cell infiltration to the tumor site, and upregulation of MHC Class I expression in tumors.
- Other names
- EDP1503 + KEYTRUDA
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on EDP1503 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDP1503 + pembrolizumab.